Who
Jasbir Seehra
Chief Executive Officer
Company insider
Files Form 4 as: Chief Executive Officer, Keros Therapeutics; Director, Eloxx Pharmaceuticals.
In numbers
- Trades disclosed
- 33
- Buys
- 1
- Sells
- 1
- Bought
- $320K
- Sold
- $227K
- Companies
- 2
- Companies where not an officer
- 1
- First trade
- 15 Jun 2018
- Last trade
- 2 Apr 2026
- Last filed
- 6 Apr 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 2 Apr 2026filed 6 Apr 2026 | KROS Keros TherapeuticsBiotechnology | SEC FORM 4 Code M | $17K55,000 at $0.30 | filing |
| 2 Apr 2026filed 6 Apr 2026 | KROS Keros Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —55,000 at $0.00 | filing |
| 2 Apr 2026filed 6 Apr 2026 | KROS Keros Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —55,000 at $0.00 | filing |
| 2 Apr 2026filed 6 Apr 2026 | KROS Keros TherapeuticsBiotechnology | SEC FORM 4 Code M | $17K55,000 at $0.30 | filing |
| 24 Feb 2026filed 26 Feb 2026 | KROS Keros Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —217,000 at $0.00 | filing |
| 24 Feb 2026filed 26 Feb 2026 | KROS Keros Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —100,000 at $0.00 | filing |
| 24 Feb 2026filed 26 Feb 2026 | KROS Keros Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —217,000 at $0.00 | filing |
| 24 Feb 2026filed 26 Feb 2026 | KROS Keros Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —100,000 at $0.00 | filing |
| 19 Feb 2026filed 20 Feb 2026 | KROS Keros TherapeuticsBiotechnology | SEC FORM 4 Sold | $113K7,015 at $16.17 | filing |
| 19 Feb 2026filed 20 Feb 2026 | KROS Keros TherapeuticsBiotechnology | SEC FORM 4 Sold | $113K7,015 at $16.17 | filing |
| 7 Jan 2026filed 9 Jan 2026 | KROS Keros Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —62,500 at $0.00 | filing |
| 7 Jan 2026filed 9 Jan 2026 | KROS Keros Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —62,500 at $0.00 | filing |
| 3 Sep 2025filed 5 Sep 2025 | KROS Keros TherapeuticsBiotechnology | SEC FORM 4 Code A | —90,500 at $0.00 | filing |
| 4 Apr 2025filed 7 Apr 2025 | KROS Keros Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —49,367 at $0.00 | filing |
| 4 Apr 2025filed 7 Apr 2025 | KROS Keros TherapeuticsBiotechnology | SEC FORM 4 Code M | $15K49,367 at $0.30 | filing |
| 23 Feb 2024filed 23 Feb 2024 | KROS Keros Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —125,000 at $0.00 | filing |
| 13 Feb 2024filed 15 Feb 2024 | KROS Keros Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —125,000 at $0.00 | filing |
| 8 Apr 2023filed 11 Apr 2023 | KROS Keros Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —4,000 at $0.00 | filing |
| 8 Apr 2023filed 11 Apr 2023 | KROS Keros TherapeuticsBiotechnology | SEC FORM 4 Code M | $1,9204,000 at $0.48 | filing |
| 16 Feb 2023filed 17 Feb 2023 | KROS Keros Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —200,000 at $0.00 | filing |
News
Reviewing Upstream Bio (NASDAQ:UPB) and Keros Therapeutics (NASDAQ:KROS)KROS · themarketsdaily.com · 12 Oct 2026
0 headlines in the last 90 days name Jasbir Seehra; 1 article from the last 14 days about the 1 company they traded most, at most three about any one of them.